3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Neoplasms
2
Thrombocythemia, Essential
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pinealoma
1
Pancreatic Cancer Metastatic
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Myeloproliferative Disorders
1
Medulloblastoma
1
Leukemia, Myelomonocytic, Chronic
1
Histiocytosis, Langerhans-Cell
1
Ependymoma
1
Carcinoma
1
Brain Neoplasms
1
Interventions
X-Rays
4
Phantoms, Imaging
4
Nuclear Medicine Department, Hospital
4
Magnetic Resonance Spectroscopy
4
regorafenib
3
Specimen Handling
3
Nivolumab
3
Cyclophosphamide
3
Biopsy
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
pembrolizumab
2
olaparib
2
larotrectinib
2
ivosidenib
2
fludarabine
2
ensartinib
2
cabozantinib
2
Etoposide
2
Docetaxel
2
tocilizumab
1
tazemetostat
1
poly ICLC
1
palbociclib
1
naxitamab
1
mifamurtide
1
humanized 3F8 anti-GD2 monoclonal antibody
1
glucarpidase
1
gamma-Glutamyl Hydrolase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Osteosarcoma
×
Celecoxib
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled